Form 4: Collegium Pharmaceutical Director Carlos V. Paya Receives Stock Grant

Director Carlos V. Paya of Collegium Pharmaceutical, Inc. was granted 19,582 restricted stock units (RSUs) on May 15, 2025.

Summary

• Carlos V. Paya, a director of Collegium Pharmaceutical, Inc., received a grant of 19,582 restricted stock units (RSUs) on May 15, 2025.
• Each RSU represents the contingent right to receive one share of Collegium Pharmaceutical's common stock.
• 9,791 of the RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders.
• The remaining 9,791 RSUs vest on May 15, 2026, contingent upon the director's continued service with the Issuer.
• The RSUs will be settled on the vesting date, or earlier upon the director's election, at the end of the director's service, death, disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of RSUs is a standard practice and indicates confidence in the company's future, but it's not a major event that would drastically alter investor sentiment.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and performance.

Future Outlook

The director's continued service is tied to the vesting of the RSUs, suggesting an expectation of ongoing involvement with the company.

Industry Context

Stock grants to directors are a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock grants, vary widely across the pharmaceutical industry depending on company size, performance, and governance practices.
• Comparing the size and vesting schedule of this RSU grant to those of directors at similar-sized pharmaceutical companies (e.g., companies with comparable market capitalization and revenue) would provide a benchmark for assessing its relative value and appropriateness.
• Companies like Teva Pharmaceutical Industries Ltd. and Mylan N.V. (now Viatris Inc.) have similar compensation structures for their directors, including stock options and restricted stock units.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with long-term company performance.
• The director is incentivized to contribute to the company's success to realize the value of the RSUs.

Key Dates

Keywords

RSU, Director, Collegium Pharmaceutical, Stock Grant, Beneficial Ownership, Form 4